THE ROLE OF PROSTANOID IN HEPATIC DAMAGE DURING HEPATECTOMY

Backgound/Aims: The aim of this study in hepatectomy is to investigate whether or not hepatic ischemia elevates the serum prostanoid levels, and whether or not thromboxane A2 (TXA2) synthetase inhibitor (OKY 04 6) improves hepatic damage. Materials and Methods: The prostanoid leve ls were measured in 22 hepatectomy cases. The beneficial effects of th romboxane A2 synthetase inhibitor were examined in cases who underwent hepatectomy under hemihepatic vascular control. The total prostanoid levels (6 ketos PG F1a + PGE2 + TXB2) were measured in 22 cases before and after hepatectomy. The hepatic ischemic time (HIT) was defined as the time required to perform a hepatic mobilization plus the right he mihepatic vascular control technique. Results: The total prostanoid le vels increased after hepatectomy (P<0.01). The changes in the total pr ostanoid levels positively correlated with the HIT (P<0.01). The 17 ca ses who underwent hepatectomy with HIT were randomly divided into 2 gr oups; the OKY group (n=9), OKY 046 (0.2 mg/kg/hr), the control group ( n=8); no drug was given. The OKY 046 administration reduced the TXB2 l evels (P<0.01), without any changes in the PGE2, or 6-keto PGF1a level s. The serum glutamic oxaloacetic transaminase levels after operation were lower, and the hepaplastin tests were higher in the OKY group tha n those of the control (P<0.05).Conclusion: These results demonstrated that hepatectomy under ischemia elevated the prostanoid levels. OKY 0 46 significantly reduced the TXB2 levels and the degree of hepatic dam age in hepatectomy under ischemia.